Ondine Biomedical

Focus: Ondine Biomedical is a public biotechnology company focused on antimicrobial photodisinfection therapy for infectious diseases, with a differentiated platform targeting surgical site infections, respiratory infections, and oral infections.

Infectious Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Open Jobs

About Ondine Biomedical

AI assessmentNot Hiring

No open roles listed right now. Follow Ondine Biomedical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Nasal Photodisinfection

COVID-19 Respiratory Infection

N/A

Clinical Trials (1)

NCT05184205Photodynamic Therapy for COVID-19 Prevention

N/A

Help build intelligence for Ondine Biomedical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Novel photodisinfection platform with multiple Phase 2-3 programs offers exposure to innovative anti-infective technology with significant unmet clinical need in surgical and healthcare-associated infections
Public company status provides equity upside potential and established infrastructure vs. early-stage biotech, with 9 active clinical programs across diverse infectious disease indications
Canadian biotech hub location (Vancouver, BC) with growing medtech/biotech ecosystem and potential visa sponsorship pathway for international talent

Watch Out For

Zero current job openings and no hiring department data suggests minimal near-term expansion or potentially challenging headcount environment
Early-stage pipeline (only 1 Phase 3, 2 Phase 2, 1 Phase 1-2 program) with no approved products means long runway to revenue and clinical/regulatory risk across all programs

Generated by Claude from Ondine Biomedical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

activated Light Source

Efficacy of Preoperative Microbial Reduction in the Nasal Cavity Using Antimicrobial Photodynamic Therapy (aPDT)

N/A

Clinical Trials (1)

NCT06570252Preoperative Microbial Reduction of the Nasal Cavity With Antimicrobial Photodynamic Therapy (aPDT).

N/A

light activated dye photodynamic therapy

Periodontitis

N/A

Clinical Trials (1)

NCT03270254Photodynamic Therapy Plus Root Debridement in Gum Disease Treatment V2

N/A